scholarly journals Combinatory Treatment with miR-7-5p and Drug-Loaded Cubosomes Effectively Impairs Cancer Cells

2020 ◽  
Vol 21 (14) ◽  
pp. 5039
Author(s):  
Ewa Gajda ◽  
Marlena Godlewska ◽  
Zenon Mariak ◽  
Ewa Nazaruk ◽  
Damian Gawel

Background: Multidrug resistance (MDR) is an emerging problem in the treatment of cancer. Therefore, there is a necessity for novel strategies that would sensitize tumor cells to the administered chemotherapeutics. One of the innovative approaches in fighting drug-resistant tumors is the treatment of cancer with microRNA (miRNA), or the use of cubosomes (lipid nanoparticles) loaded with drugs. Here, we present a study on a novel approach, which combines both tools. Methods: Cubosomes loaded with miR-7-5p and chemotherapeutics were developed. The effects of drug- and miRNA-loaded vehicles on glioma- (A172, T98G), papillary thyroid- (TPC-1) and cervical carcinoma-derived (HeLa) cells were analyzed using molecular biology techniques, including quantitative real-time PCR, MTS-based cell proliferation test, flow cytometry and spheroids formation assay. Results: The obtained data indicate that miR-7-5p increases the sensitivity of the tested cells to the drug, and that nanoparticles loaded with both miRNA and the drug produce a greater anti-tumor effect in comparison to the free drug treatment. It was found that an increased level of apoptosis in the drug/miRNA co-treated cells is accompanied by an alternation in the expression of the genes encoding for key MDR proteins of the ABC family. Conclusions: Overall, co-administration of miR-7-5p with a chemotherapeutic can be considered a promising strategy, leading to reduced MDR and the induction of apoptosis in cancer cells.

2020 ◽  
Vol 1 (8) ◽  
pp. 3033-3048
Author(s):  
Manosree Chatterjee ◽  
Ritwik Maity ◽  
Souvik Das ◽  
Nibedita Mahata ◽  
Biswarup Basu ◽  
...  

A novel approach used to synthesize antimetabolite-conjugated and intense blue fluorescence-emitting smart polymeric nanoparticles is reported for the efficient delivery of anticancer drugs and self-monitoring their effect in drug-resistant metastatic breast cancer cells.


Biomolecules ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 358 ◽  
Author(s):  
Alvinsyah Adhityo Pramono ◽  
Gulam M. Rather ◽  
Herry Herman ◽  
Keri Lestari ◽  
Joseph R. Bertino

Actively proliferating cancer cells require sufficient amount of NADH and NADPH for biogenesis and to protect cells from the detrimental effect of reactive oxygen species. As both normal and cancer cells share the same NAD biosynthetic and metabolic pathways, selectively lowering levels of NAD(H) and NADPH would be a promising strategy for cancer treatment. Targeting nicotinamide phosphoribosyltransferase (NAMPT), a rate limiting enzyme of the NAD salvage pathway, affects the NAD and NADPH pool. Similarly, lowering NADPH by mutant isocitrate dehydrogenase 1/2 (IDH1/2) which produces D-2-hydroxyglutarate (D-2HG), an oncometabolite that downregulates nicotinate phosphoribosyltransferase (NAPRT) via hypermethylation on the promoter region, results in epigenetic regulation. NADPH is used to generate D-2HG, and is also needed to protect dihydrofolate reductase, the target for methotrexate, from degradation. NAD and NADPH pools in various cancer types are regulated by several metabolic enzymes, including methylenetetrahydrofolate dehydrogenase, serine hydroxymethyltransferase, and aldehyde dehydrogenase. Thus, targeting NAD and NADPH synthesis under special circumstances is a novel approach to treat some cancers. This article provides the rationale for targeting the key enzymes that maintain the NAD/NADPH pool, and reviews preclinical studies of targeting these enzymes in cancers.


Phytomedicine ◽  
2019 ◽  
Vol 60 ◽  
pp. 152832 ◽  
Author(s):  
Armelle T. Mbaveng ◽  
Gabin T.M. Bitchagno ◽  
Victor Kuete ◽  
Pierre Tane ◽  
Thomas Efferth

2019 ◽  
Vol 112 (1) ◽  
Author(s):  
Zhaoqianqi Feng ◽  
Huaimin Wang ◽  
Meihui Yi ◽  
Chieh‐Yun Lo ◽  
Ashanti Sallee ◽  
...  

Autophagy ◽  
2021 ◽  
Author(s):  
Michael S. Dahabieh ◽  
Fan Huang ◽  
Christophe Goncalves ◽  
Raúl Ernesto Flores González ◽  
Sathyen Prabhu ◽  
...  

RSC Advances ◽  
2021 ◽  
Vol 11 (7) ◽  
pp. 4163-4163
Author(s):  
Laura Fisher

Retraction of ‘Overexpression of PCDH8 inhibits proliferation and invasion, and induces apoptosis in papillary thyroid cancer cells’ by Liang Chang et al., RSC Adv., 2018, 8, 18030–18037, DOI: 10.1039/C8RA02291G.


2009 ◽  
Vol 19 (15) ◽  
pp. 4255-4258 ◽  
Author(s):  
Tayyab A. Mansoor ◽  
Rita M. Ramalho ◽  
Silva Mulhovo ◽  
Cecília M.P. Rodrigues ◽  
Maria José U. Ferreira

Sign in / Sign up

Export Citation Format

Share Document